T
here are many risk factors that influence renal function, such as drugs with renal toxicity, infection, heart failure, etc. The estimated glomerular filtration rate (eGFR) is the main index for evaluating renal function. 1 Patients with decreased eGFR are less capable of enduring disease attacks; thus, they have poor outcomes when subjected to infection, heart failure, and so on. Clinicians attach importance to renal function and its associated risk factors in the elderly. Although aging is an indispensable factor, comorbidities can also contribute to the rate of eGFR decrease. 2 Controlling blood pressure and glucose are important methods for maintaining renal function in elderly patients, but blood pressure and glucose control can only partially slow down the rate of eGFR decline. Previous studies have shown that hypertension and cardiovascular diseases are detrimental to long-term renal function because they cause hyperfiltration in the glomeruli; however, little is known about the relationship between left ventricular hypertrophy (LVH) and renal function in elderly patients with non-end-stage renal disease (non-ESRD). 3 Heart disease is a major risk factor of kidney damage, the prognosis of which depends on not only blood pressure level but also associated factors such as LVH. 4 The latter frequently develops among patients with hypertension or cardiovascular diseases. Several echocardiography studies have indicated that chronic kidney disease (CKD) is independently associated with the presence of LVH, suggesting that renal function is related to left ventricular mass index (LVMI). [5] [6] [7] Furthermore, the results of experimental and animal studies also support the association between CKD and LVMI. LVH emerges as an adaptive response to overload, such as pressure or volume, to some extent, but long-term LVH leads to left ventricular dysfunction, resulting in the constriction of the renal arteries, less blood-perfusion of the glomeruli, and alteration of the glomerular membrane filtration coefficient and tubular reabsorption. 8, 9 The inflammatory response associated with LVH also contributes to the progression of CKD. 10 Thus, LVH appears to be a type of adverse cardiac remodeling that contributes to risk factors of CKD. We hypothesized that LVH patients would have a rapid rate of eGFR decline due to adverse cardiac remodeling. The aim of the present study was to evaluate the association of renal function with left ventricular structural alterations in a clinicbased sample of consecutive patients.
Methods Approvals
All experiments were performed following the relevant guidelines and regulations of Capital Medical University. This study was approved by the Medical Ethics Committee of Capital Medical University (No. IRB00005735). All study participants gave both verbal and written informed consent before study enrollment.
Study Design and Patients
We performed a retrospective cohort study to compare the rate of renal function decline between non-ESRD elderly patients with or without LVH. We enrolled 300 in-and outpatients (>60 years of age) from January 2000 to December 2010 at Beijing Friendship Hospital who had complete echocardiography, renal function, and other basic medical and laboratory information. The patients who had no complete echocardiography or renal function examination within 1-year follow-up were excluded. LVH was defined as LVMI ≥125 g/ m 2 in men and LVMI ≥110 g/m 2 in women. 11 Rapid kidney function decline (RKFD) was defined as a decline in eGFR of at least 5 mL/min per 1.73 m 2 for 12 months. 9 The exclusion criteria were as follows: eGFR ≤15 
Collection of Demographic, Medical, and Laboratory Data
Demographic and medical data, including age, sex, and comorbid conditions were obtained from medical records or patient interviews. Body mass index was calculated as the weight in kilograms divided by the square of the height in meters. Blood pressure was measured with subjects in the supine position, using a mercury sphygmomanometer with an appropriate cuff on the left arm; the average of 2 readings was used for the statistical analysis. Heart rate was counted over a full minute.
A 12-hour overnight fasting venous blood sample was collected for measurements of total cholesterol, high-density lipoprotein, triglycerides, low-density lipoprotein, plasma glucose, serum uric acid, blood urea nitrogen (BUN), hemoglobin (Hgb), calcium, and phosphorus.
According to the K/DIGO-2012 guidelines, 12 
Results

Baseline Characteristics
The comparisons of demographic and clinical data between the LVH patients and non-LVH controls are presented in were significantly higher in the LVH patients than in the controls. We did not rule out the possible interference of therapeutic drugs in the study; thus, the eGFR and prevalence of hypertension may not have been different between subjects with and without LVH. As elderly persons often have comorbidities that can contribute to the prevalence of LVH and the rate of eGFR decline, the proportion of elderly persons without LVH may be relatively less than that among younger individuals. As shown in Table 2 , the LVH group had a larger left atrial diameter (P=0.032), end-diastolic diameter (P=0.033), end-systolic diameter (P=0.020), left ventricular mass (P=0.023), and LVMI (P<0.001) compared to the control group.
eGFR Decline Speed Changes Showed That Renal Function Tended to Decline Faster in the LVH Group Than in the Non-LVH Group
To determine whether LVH affects the rate of renal function decline, we compared the eGFR changes between the 2 study groups. The eGFR change for all patients was À2.06AE8.63 mL/ min per 1.73 m 2 . As shown in Figure 1 , the eGFR change for the LVH group was negative (À2.49AE8.98 mL/min per 1.73 m 2 ) and the eGFR change in the non-LVH group was positive (0.15AE6.10 mL/min per 1.73 m 2 ). The decrease in renal function was significantly greater in the LVH group than in the non-LVH group (P=0.013), although the eGFR was nearly stable in both groups.
Univariate Logistic Regression Analysis
To compare the rate of renal function decline between the patients with and without LVH, we performed univariate analyses. As shown in Table 3 , the factors associated with RKFD were Hgb (odds ratio 0.981; 95% CI 0.967-0.996; P=0.015), BUN (odds ratio 1.037; 95% CI 0.997-1.079; P=0.069), LVH (odds ratio 4.291; 95% CI 1.759-10.465; P=0.001) and dyslipidemia (odds ratio 1.794; 95% CI 1.105-2.913; P=0.018). In contrast, body mass index, diabetes mellitus, and systolic and diastolic blood pressure were not associated with RKFD.
Multivariable Logistic Analysis
The multivariable logistic analysis showed that baseline eGFR, Hgb level, BUN, LVH, and dyslipidemia were associated with RKFD. The Hgb level was negatively correlated with the incidence of RKFD, while baseline eGFR and BUN were positively correlated with it. Patients with LVH had a much higher risk of RKFD than patients without LVH. The logistic regression analysis results and the specific odds ratios are shown in Table 4 .
Comparison of LVMI Between the Non-CKD Group and Different Subgroups of CKD Patients
To compare LVMI in different subgroups of CKD patients, we classified all patients into 3 subgroups: non-CKD, mild CKD (eGFR ≥60 mL/min per 1.73 m 2 ), and severe CKD (eGFR 
Discussion
In the present study, we enrolled 300 elderly Chinese patients, most of whom had chronic diseases. All patients were under antihypertensive and lipid-lowering treatments. Echocardiography was performed on all patients in order to evaluate cardiac function and calculate LVMI. The prevalence of LVH in the present study was much higher than that reported in the general population. [13] [14] [15] The majority of patients included in this study had hypertension, chronic heart disease, or CKD at the time of enrollment, but their blood pressures were normal (130/70 mm Hg). Patients with LVH had a slightly higher mean blood pressure than patients without LVH, but this difference was not statistically significant (133/72 versus 130/70 mm Hg; P=0.105/0.067). Diabetes mellitus was present in 38.7% of the study subjects, and more than two thirds of the enrolled participants had CKD. Previous studies have shown that the prevalence of LVH is higher in CKD patients and tends to increase with the Moreover, in the univariate logistic regression analyses, Hgb, BUN, LVH, and dyslipidemia were associated with a higher incidence of RKFD. Considering that many studies have shown that both eGFR and albuminuria can predict the relative risk of RKFD, we included baseline eGFR and 4 other factors in the multivariate logistic analysis. After adjusting for several potential confounders, the analysis showed that the incidence rate of RKFD was significantly associated with LVH: the incidence of RKFD was %4.5-fold higher in the LVH group than in the non-LVH group.
The following is a potential explanation for how LVH accelerates the rate of eGFR decline and causes RKFD: (1) One of the predominant causes of LVH is hypertension, as it can lead to constriction of the renal arteries, afferent arterioles, and efferent arterioles and alter the glomerular membrane filtration coefficient and tubular reabsorption. 23 (2) Long-term LVH can induce left ventricular dysfunction and decrease blood perfusion in the glomeruli, resulting in renal tubular ischemia. (3) In patients with LVH, the associated inflammatory response, indicated by, for example, elevated plasma levels of high-sensitivity C-reactive protein and interleukin-6, may contribute to and accelerate the progression of systolic dysfunction and cause rapid progression of CKD. 10 However, the blood pressure and ejection rate were not significantly different between the LVH and non-LVH groups in our study. Thus, there must be other pathophysiologic agents that increase the rate of renal impairment in LVH patients. The association between CKD and LVH is well known; hypertension and volume overload are major causes of CKD. It was reported that about 75% of adults that suffered CKD have LVH. Siedlecki et al identify additional mechanisms that load-independent primary stimuli trigger or contribute to ventricular hypertrophy in uremia. 24 Consistent with previous studies of RKFD and eGFR, a lower baseline eGFR is a risk factor for RKFD. 25, 26 BUN was also found to be independently associated with RKFD, and a lower Hgb was found be associated with a slightly higher risk of RKFD. Participants in the non-CKD group were younger than those in the CKD group, probably because renal function decreases with aging and is an important factor in the increased prevalence of CKD in the elderly. 27, 28 The Hgb level in the non-CKD group was the highest among the 3 CKD groups. This might be because less erythrogenin is secreted by impaired kidneys. The levels of BUN and uric acid increased with renal injury severity. Although left atrial diameter, end-diastolic diameter, end-systolic diameter, ejection fraction, intraventricular septum thickness, and posterior wall thickness in diastole were not significantly different between the 3 groups, LVMI was higher in the CKD group. Previous studies found that ESRD induced LVH through the induction of hypertension or anemia, 16 but few studies discussed LVMI changes in non-ESRD patients. Our study showed that moderate renal function injury tended to be associated with a higher LVMI, even though the blood pressure levels of the patients in our study were within the normal range. However, some limitations of this retrospective cohort study must be considered: (1) This study only focused on elderly patients; therefore, the conclusions made here cannot be generalized to patients below 60 years of age. (2) The non-LVH group contained fewer patients than the LVH group, and the follow-up duration was relatively short. (3) The possibility of interference from therapeutic drugs was not excluded. (4) The baseline characteristics demonstrated that the samples were predominantly male and the effect modification by sex was not evaluated.
In conclusion, the results of this study showed that LVH is positively associated with renal function decline and a subsequent increased risk of RKFD; therefore, regression of LVH may serve not only to decrease cardiovascular mortality but also to maintain renal function.
